In the Claims:

1. (Withdrawn) A method of treating a HIV comprising of:

the use of at least one polypeptide including an amino acid sequence from the group consisting of KPV, MEHFRWG, HFRWGKPV, SYSMEHFRWGKPV or a biologically functional equivalent of any of the foregoing.

- 2. (Withdrawn) The method of claim 1 wherein the HIV is accompanied by the presence of bacteria or fungi or both.
- 3. (Withdrawn) The method of claim 2 wherein the bacteria present is from the genus *Staphylococcus*.
- 4. (Withdrawn) The method of claim 2 wherein the bacteria present is Staphylococcus aereus.
- 5. (Withdrawn) The method of claim 2 wherein the fungi present is from the genus *Candida*.
- 6. (Withdrawn) The method of claim 2 wherein the fungi present is *Candida* albicans.
- 7. (Withdrawn) The method of claim 1 wherein the amino acid sequence KPV, HFRWGKPV, or SYSMEHFRWGKPV is located at the C-terminal of at least one polypeptide.
- 8. (Withdrawn) The method of claim 1 wherein the amino acid sequences KPV, HFRWGKPV, MEHFRWG, or SYSMEHFRWGKPV includes at least one amino acid in the D-form.

- 9. (Withdrawn) The method of claim 1 wherein at least one polypeptide is N-acetylated or C-amidated or both.
- 10. (Withdrawn) The method of claim 1 wherein at least one polypeptide includes a dimer from any amino acid sequence in the group in claim 1.
 - 11. (Withdrawn) The method of claim 2 wherein the dimer is a KPV dimer.
 - 12. (Withdrawn) A method of treating a HIV comprising of:

the use of at least one polypeptide including an amino acid sequence form the group consisting of KPV, MEHFRWG, HFRWGKPV, SYSMEHFRWGKPV or a biologically functional equivalent of any of the foregoing in a pharmaceutically appropriate amount contained in one of the carriers from the following group consisting of a solution for injection, a liquid, a pill, a capsule, a suppository, and an inhaler.

13. (Currently Amended) A method for treating secondary inhibiting opportunistic infections in a-an HIV-infected individual comprising: administering to the individual a pharmaceutically appropriate amount of a KPV tripeptide., and wherein the KPV is anti-microbial.

biologically functional equivalent of any of the foregoing.

15. (Currently Amended) The method of claim 13, wherein the KPV tripeptide is contained in a carrier selected from the group consisting of a solution for



injection, a liquid, a pill, a capsule, a cream, an ointment, a gel, a suppository, an aerosol spray, and an inhaler.

- 16. (Currently Amended) A method for treating secondary inhibiting opportunistic infections in a an HIV-infected individual comprising: administering a KPV tripeptide composition in a pharmaceutically appropriate amount to the HIV-infected individual wherein the KPV tripeptide composition comprises the KPV tripeptide and a carrier, and the KPV is anti-microbial.
- 17. (Currently Amended) The method of claim 16, wherein the KPV tripeptide composition is administered orally, parenterally, locally or topically.
- 18. (Previously Presented) The method of claim 16, wherein the carrier is water, saline, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oil, polyalkylene-glycol, petroleum jelly, a solution, a suspension, an ointment, a cream, a powder, a gel, or an aerosol.
- 20. (Previously Presented) The method of claim 19, wherein the additive is a flavoring, a preservative, a stabilizer, a emulsifier, a buffer or a combination thereof.
- 21. (Previously Presented) The method of claim 16, wherein the pharmaceutically appropriate amount for an oral administration is about 1-10 milligrams/kg.
- 22. (Previously Presented) The method of claim 16, wherein the pharmaceutically appropriate amount for an intravenous administration is about 1-10 micrograms/kg.



- 23. (Currently Amended) The method of claim 16, wherein the KPV tripeptide composition comprises 10-40% by weight of the KPV tripeptide composition for a topical administration.
- 24. (Currently Amended) A method for enhancing the killing of a pathogen inhibiting bacterial or fungal infections in a an HIV-infected individual comprising administering to the HIV-infected individual a pharmaceutically appropriate amount of a KPV tripeptide. wherein the KPV is anti-microbial.
- 25. (Currently Amended) The method of claim 24, wherein the KPV tripeptide is contained in a carrier selected from the group consisting of a solution for injection, a liquid, a pill, a capsule, a cream, an ointment, a gel, a suppository, an aerosol spray, and an inhaler.
- 26. (Currently Amended) A method for enhancing the killing of a pathogen inhibiting bacterial or fungal infections in a an HIV-infected individual comprising: administering a KPV tripeptide composition in a pharmaceutically appropriate amount to the HIV-infected individual, wherein the KPV tripeptide comprises a KPV and a carrier and the KPV is anti-microbial composition comprises a KPV tripeptide and a carrier.
- 27. (Currently Amended) The method of claim 26, wherein the KPV tripeptide composition is administered orally, parenterally, locally or topically.
- 28. (Previously Presented) The method of claim 26, wherein the carrier is water, saline, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oil, polyalkylene-glycol, petroleum jelly, a solution, a suspension, an ointment, a cream, a powder, a gel, or an aerosol.





- 29. (Currently Amended) The method of claim 26, wherein the KPV tripeptide composition further comprises an additive.
- 30. (Previously Presented) The method of claim 29, wherein the additive is a flavoring, a preservative, a stabilizer, a emulsifier, a buffer or a combination thereof.
- 31. (Previously Presented) The method of claim 26, wherein the pharmaceutically appropriate amount for an oral administration is about 1-10 milligrams/kg.
- 32. (Previously Presented) The method of claim 26, wherein the pharmaceutically appropriate amount for an intravenous administration is about 1-10 micrograms/kg.



33. (Currently Amended) The method of claim 26, wherein the KPV tripeptide in the KPV tripeptide composition comprises 10-40% by weight of the KPV tripeptide composition for a topical administration.